Vol 16, No 3 (2020)
Guidelines / Expert consensus
Published online: 2020-07-08

open access

Page views 527
Article views/downloads 652
Get Citation

Connect on Social Media

Connect on Social Media

Supportive care. Neutropenia

Piotr Potemski, Rafał Czyżykowski
Oncol Clin Pract 2020;16(3):87-96.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Common Terminology Criteria for Adverse Events (Version 5.0). Dostęp on-line: 10.01.2020 (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf).
  2. Klastersky J, de Na, Rolston K, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(supl. 5): v111–v118.
  3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4): e56–e93.
  4. NCCN Guidelines Version 1.2020. Prevention and treatment of cancer-related infections. Dostęp on-line: 10.01.2020.
  5. Crawford J, Caserta C, Roila F, et al. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010; 21 Suppl 5: v248–v251.
  6. Kamana M, Escalante C, Mullen CA, et al. Bacterial infections in low-risk, febrile neutropenic patients. Cancer. 2005; 104(2): 422–426.
  7. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007; 30 Suppl 1: S51–S59.
  8. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16): 3038–3051.
  9. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008; 32 Suppl 1: S30–S33.
  10. Singer M, Deutschman C, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801.
  11. Raad I, Hanna HA, Alakech B, et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004; 140(1): 18–25.
  12. Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014(10): CD003039.
  13. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors. Dostęp on-line: 15.11.2019.
  14. Smith TJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(28): 3199–3212.
  15. Sung L, Nathan PC, Alibhai SMH, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007; 147(6): 400–411.
  16. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010; 28(17): 2914–2924.
  17. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013; 24(10): 2475–2484.
  18. Aapro MS, Bohlius J, Cameron DA, et al. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47(1): 8–32.